Latest Breaking News On - Head of research development - Page 1 : vimarsana.com

Women in Manufacturing Summit 2024: 20-22 August, Melbourne

Following last year's standout event, the Women in Manufacturing Summit 2024 is coming to Melbourne this August with exciting new speakers, all new content, engaging new formats, and more opportunities to meet, learn from and build relationships with your peers in the industry.

Serena rossHannah campbellJayne glassonKate whitneyHoni walkerClair edwardsDonna paxtonKarin vosmanskyLaura besleyCarissa mansfieldHead of research developmentGroup human resourcesMelbourne manufacturers allianceCircuitwise electronics manufacturingManufacturing summitChief executive officer

Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024

MALVERN, Pa., May 20, 2024 Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun.

British columbiaTarun upadhyayExchange commissionInternational society for cell gene therapyVancouver convention centreOcugen incHead of research developmentHead of communicationsChief scientific officerInternational societyGene therapyAnnual meetingBreaking oral abstract sessionEfficacy resultsPoster networking sessionPrivate securities litigation reform act

6G: The Next Technological Leap The Future is Here!

6G: The Next Technological Leap The Future is Here!
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

Andhra pradeshNew delhiUnited statesSanjay kumarSaurabh mittalShashi dharanAshwani ranaSanjeev kumarManoj gurnaniMahesh basavarajuA robert jerard raviVikesh sharmaSoumen bhowmikBharti airtelDinesh chand sharmaRohit kumar

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKanya rajangamSecurities exchangeSenti biosciences incHead of research developmentExchange commissionLogic gatedGene circuitChief medical officerSenti bioGene circuitsSpark therapeuticsSecurities actSecurities exchange actQuarterly reportSenti biosciences

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesKanya rajangamHead of research developmentExchange commissionSenti biosciences incSecurities exchangeLogic gatedGene circuitChief medical officerSenti bioGene circuitsSpark therapeuticsSecurities actSecurities exchange actQuarterly reportSenti biosciences